But the Glivec case is very relevant if the concern is Indian pharma industry’s future, and surely the government should be concerned about this. Nicholas Piramal is working to innovate on Glivec’s formulation. Section 3 (d) of the Indian patent law, which Novartis challenged, cannot give Nicholas Piramal a patent. Novartis is working on an anti-dengue formulation. Indian pharma companies may not want to innovate on Novartis’s molecule, which will be patented of course and produce a domestic patentable version. India’s pharma sector needs to grow out of its generic stage. But since its budget is much lower than that of Western MNCs, seeking patents on incremental innovation rather than developing new molecules is the best current strategy. That strategy receives no incentive from India’s patent law.